Physician

Majd Isreb, M.D.

According to 2025 Medicare claims, Majd Isreb, M.D. (NPI: 1669426243) practices nephrology in the Longview-Kelso, WA market, with the plurality of this provider's patient population coming from Cowlitz, WA. This provider's primary affiliated billing organization is PEACEHEALTH (NPI: 1720056187; TIN: 910564987) and primary practice location at 98632-3256. Isreb is affiliated with the PSW ACO (ACO ID: A5323) and PeaceHealth Direct Contracting LLC (ACO ID: D0152), participating under both the MSSP and REACH models.

Isreb's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 261 traditional Medicare patients, billed 1,180 HCPCS/CPT codes, and received $135,689 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,716 prescription claims across 380 beneficiaries totaling $239,494 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 158 claims. Open Payments data shows 1 records totaling $119. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	386	1,538	$162,668
2016	403	1,479	$158,016
2017	427	1,667	$184,473
2018	403	1,596	$190,477
2019	467	1,860	$206,789
2020	457	1,667	$181,520
2021	378	1,380	$192,377
2022	336	1,252	$171,426
2023	288	1,024	$141,362
2024	261	1,180	$135,689

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	300	3,104	$452,575
2016	261	2,500	$318,386
2017	271	2,431	$366,318
2018	272	2,560	$256,361
2019	274	2,341	$146,003
2020	277	2,277	$168,665
2021	317	2,476	$210,013
2022	311	2,323	$232,760
2023	332	2,573	$277,732
2024	380	2,716	$239,494

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	170	$10,167
2016	N/R	229	$11,618
2017	N/R	259	$12,109
2018	11	317	$17,907
2019	11	298	$13,517
2020	N/R	310	$14,236
2021	11	288	$12,182
2022	23	278	$8,335
2023	23	280	$11,465
2024	N/R	158	$2,790

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	28	192	$278
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	32	33	$127
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	124	214	$67
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	98	143	$43
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	153	252	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	50	2,280	$43,603
Jardiance	Empagliflozin	40	1,518	$26,753
Sevelamer Carbonate	Sevelamer Carbonate	125	4,937	$18,971
Kerendia	Finerenone	25	810	$17,664
Eliquis	Apixaban	16	660	$12,804

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	32	$1,040
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	47	$828
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	41	$493
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	23	$419
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	15	$10

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$119	Ardelyx, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Majd Isreb, M.D.?

Tedicare shows public-source Medicare data for Majd Isreb, M.D. (NPI 1669426243), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Majd Isreb, M.D. have ACO affiliation data?

Majd Isreb, M.D. is shown with ACO affiliation data for PSW ACO (MSSP, ACO ID A5323) and PeaceHealth Direct Contracting LLC (REACH, ACO ID D0152).

What billing organization is linked to Majd Isreb, M.D.?

Majd Isreb, M.D. is linked to PEACEHEALTH (billing NPI 1720056187) in the available physician profile data.

Does Majd Isreb, M.D. have Open Payments data?

Majd Isreb, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.